FDA Clears Lumen Biomedical’s FiberNet Embolic Protection System for Carotid Artery Stenting


November 20, 2008

November 20, 2008 - Lumen Biomedical Inc. said today the FDA cleared its FiberNet Embolic Protection System (EPS) for the treatment of patients receiving endovascular intervention for carotid artery disease.

The approval follows the recent release of the EPIC Clinical Study data demonstrating the lowest stroke rates of any filter currently available on the U.S. market, the manufacturer said.

The FiberNet EPS captures debris released during the stenting procedure and prevents it from traveling to the brain, where it has the potential to cause a stroke. The defining attribute of the FiberNet filter lies in the three-dimensional design, comprised of a matrix of fibers, allowing for better capture efficiency (> 40 μm). The low-profile filter is mounted on a guide wire, needing no delivery system to cross the lesion. Remote actuation deploys the fiber-based filter - treating vessels ranging from 3.5 to 7mm - filling the vessel and ensuring excellent wall apposition. After the particles have been captured, the FiberNet filter is retrieved into the retrieval catheter under aspiration, and removed from the patient.

“The optimal filtration and ease of use of the FiberNet filter have proven to be clinically significant advancements in the carotid arena,” said Subbarao Myla, M.D., U.S. co-principal investigator of the EPIC trial. “The 2.1 percent 30-day stroke rate achieved in the EPIC trial further strengthens the parallel between technological advancements and the safety of carotid stenting.”

The FiberNet EP System was evaluated in the multi-center, EPIC trial during carotid artery stenting of 237 high surgical risk patients with a critical carotid artery stenosis. Overall, the combined major adverse event rate at 30 days for all death, stroke and myocardial infarction was 3 percent. There were five strokes (four ischemic and one hemorrhagic) for a 30-day stroke rate of 2.1 percent. There were no unanticipated adverse device effects.

For more information: www.lumenbio.com